Free Trial
NASDAQ:AYTU

Aytu BioPharma (AYTU) Stock Price, News & Analysis

Aytu BioPharma logo
$2.46 -0.08 (-3.31%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Aytu BioPharma Stock (NASDAQ:AYTU)

Key Stats

Today's Range
$2.38
$2.60
50-Day Range
$1.49
$2.65
52-Week Range
$0.95
$2.85
Volume
86,048 shs
Average Volume
654,233 shs
Market Capitalization
$22.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Aytu BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

AYTU MarketRank™: 

Aytu BioPharma scored higher than 82% of companies evaluated by MarketBeat, and ranked 192nd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aytu BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aytu BioPharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about Aytu BioPharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aytu BioPharma is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aytu BioPharma is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aytu BioPharma has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Aytu BioPharma's valuation and earnings.
  • Percentage of Shares Shorted

    9.12% of the float of Aytu BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Aytu BioPharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aytu BioPharma has recently decreased by 21.17%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Aytu BioPharma does not currently pay a dividend.

  • Dividend Growth

    Aytu BioPharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.12% of the float of Aytu BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Aytu BioPharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aytu BioPharma has recently decreased by 21.17%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Aytu BioPharma has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Aytu BioPharma this week, compared to 0 articles on an average week.
  • Search Interest

    4 people have searched for AYTU on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aytu BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.60% of the stock of Aytu BioPharma is held by insiders.

  • Percentage Held by Institutions

    Only 33.49% of the stock of Aytu BioPharma is held by institutions.

  • Read more about Aytu BioPharma's insider trading history.
Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AYTU Stock News Headlines

I warned you about Nvidia… now look what’s happening
Nvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.
See More Headlines

AYTU Stock Analysis - Frequently Asked Questions

Aytu BioPharma's stock was trading at $1.70 at the beginning of 2025. Since then, AYTU stock has increased by 49.1% and is now trading at $2.5350.

Aytu BioPharma Inc. (NASDAQ:AYTU) announced its quarterly earnings data on Wednesday, May, 14th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.37. The business had revenue of $18.45 million for the quarter, compared to analyst estimates of $13.74 million. Aytu BioPharma had a trailing twelve-month return on equity of 3.51% and a net margin of 2.37%.
Read the conference call transcript
.

Aytu BioPharma's stock reverse split on Tuesday, August 29th 2017.The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional investors of Aytu BioPharma include Kanen Wealth Management LLC (6.38%). Insiders that own company stock include Joshua R Disbrow and Greg Pyszczymuka.
View institutional ownership trends
.

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), GE Aerospace (GE), CymaBay Therapeutics (CBAY) and Adobe (ADBE).

Company Calendar

Last Earnings
5/14/2025
Today
7/30/2025
Next Earnings (Estimated)
9/24/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AYTU
CIK
1385818
Fax
N/A
Employees
160
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$8.00
Potential Upside/Downside
+293.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.84 million
Net Margins
2.37%
Pretax Margin
-0.78%
Return on Equity
3.51%
Return on Assets
0.91%

Debt

Debt-to-Equity Ratio
0.27
Current Ratio
1.03
Quick Ratio
0.87

Sales & Book Value

Annual Sales
$81 million
Price / Sales
0.28
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.64 per share
Price / Book
0.55

Miscellaneous

Outstanding Shares
8,980,000
Free Float
8,654,000
Market Cap
$22.81 million
Optionable
Not Optionable
Beta
0.13
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:AYTU) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners